Embecta Corp. (NASDAQ:EMBC – Get Free Report) declared a quarterly dividend on Friday, August 7th. Shareholders of record on Thursday, August 27th will be paid a dividend of 0.01 per share on Tuesday, September 15th. This represents a c) annualized dividend and a yield of 0.9%. The ex-dividend date is Thursday, August 27th.
Embecta has a payout ratio of 1.4% meaning its dividend is sufficiently covered by earnings. Analysts expect Embecta to earn $1.75 per share next year, which means the company should continue to be able to cover its $0.04 annual dividend with an expected future payout ratio of 2.3%.
Embecta Trading Up 26.3%
EMBC opened at $4.42 on Friday. The company has a market cap of $262.24 million, a P/E ratio of 2.33 and a beta of 0.81. The company’s 50 day moving average is $3.34 and its 200-day moving average is $6.66. Embecta has a 1-year low of $2.77 and a 1-year high of $15.55.
Embecta News Summary
Here are the key news stories impacting Embecta this week:
- Positive Sentiment: Q3 earnings and revenue beat estimates: Embecta reported adjusted EPS of $0.56, exceeding the $0.27 consensus estimate, while revenue of $271.7 million topped expectations of $254.5 million. Embecta Q3 earnings report
- Positive Sentiment: Full-year EPS outlook raised: Management provided fiscal 2026 EPS guidance of $1.80–$1.90, above the $1.60 analyst consensus, signaling stronger expected profitability despite business pressures. Embecta fiscal 2026 results
- Positive Sentiment: Dividend maintained: Embecta declared a quarterly cash dividend of $0.01 per share, providing a modest continuing shareholder return. Embecta dividend announcement
- Neutral Sentiment: Strategic diversification: Embecta reiterated its plan to expand beyond insulin delivery into a broader medical-supplies business. The strategy could create longer-term growth opportunities, but the release provided limited detail on execution or near-term returns. Embecta company announcement
- Negative Sentiment: Sales remain under pressure: Quarterly revenue fell 8.1% year over year to $271.7 million, and EPS declined from $1.12 in the comparable period. This highlights ongoing weakness in Embecta’s core operations even with the earnings beat. Embecta earnings details
- Negative Sentiment: Securities-fraud lawsuit adds risk: Multiple law firms publicized a class action alleging Embecta and certain executives misrepresented the commercial stability of its insulin pen-needle business. The August 17 lead-plaintiff deadline increases visibility around potential legal costs, damages and reputational risk. Embecta securities-fraud lawsuit notice
About Embecta
Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.
The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.
Read More
- Five stocks we like better than Embecta
- Why These 3 Equal Weight ETFs Have Outperformed the S&P This Year
- MarketBeat Week in Review – 08/03 – 08/07
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.
